Health ProductsDear Healthcare Professional Letter

Archived – Association of DESYREL (Trazodone) with Drug Interactions with Medications that Alter CYP 3A4 Metabolism

· Published by Health Canada · Official notice

Details

Alert type: Dear Healthcare Professional Letter
Category: Drugs
Issue: Important Safety Information
Audience: Healthcare Professionals
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Introduction

This is duplicated text of a letter from Bristol-Myers Squibb Canada.
Contact the company for a copy of any references, attachments or enclosures.

Notice about Health Canada advisories

Details

Health Canada Endorsed Important Safety Information on DESYREL (trazodone)

June 30th, 2004

Subject: Association of Desyrel® (trazodone) with drug interactions with medications that alter CYP 3A4 metabolism

Dear Health Care Professional,

Bristol-Myers Squibb Canada (BMSC) would like to advise you of important safety information concerning the antidepressant trazodone hydrochloride tablets. Trazodone, sold by BMSC under the trade name Desyrel®, is indicated for the symptomatic relief of depressive illness. A Dear Healthcare Professional Letter was issued in the United States on May 12, 2004. Following discussions with Health Canada concerning the association of Desyrel® with drug interactions with CYP 3A4 inhibitors including ketoconazole, ritonavir, indinavir, and a CYP3A4 inducer, carbamazepine, the same information is being distributed in Canada. See attached copy. We are now working with Health Canada to update the Canadian labelling.

In vitro drug metabolism studies suggest that there is a potential for drug interactions when trazodone is given with drugs that alter metabolism by CYP3A4, leading to adverse effects including nausea, hypotension and syncope.

Please be advised that the reporting rates determined on the basis of spontaneously reported post-marketing adverse events are generally presumed to underestimate the risks associated with drug treatments.

The identification, characterization, and management of marketed health product-related adverse reactions are dependent on the active participation of health care professionals in adverse reaction reporting programmes. Any occurrences of drug interactions with Desyrel® (trazodone) and drugs that alter CYP3A4 metabolism or other serious and/or unexpected adverse reactions in patients should be reported to Bristol-Myers Squibb Canada at 1-866-463-6267 or by fax at 1-888-267-6211 or to Health Canada at the following addresses:

Bristol-Myers Squibb Canada
2365 Côte-de-Liesse
Saint-Laurent (Québec)
H4N 2M7

Any suspected adverse reaction can also be reported to:
Canadian Adverse Drug Reaction Monitoring Program (CADRMP)
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 0701C
OTTAWA, Ontario, K1A 0K9
Tel: (613) 957-0337 or Fax: (613) 957-0335
To report an Adverse Reaction, consumers and health professionals may call toll free:
Tel: 866 234-2345
Fax: 866 678-6789
cadrmp@hc-sc.gc.ca

For other inquiries: please refer to contact information.

The AR Reporting Form and the AR Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.

Any questions from health care professionals may be directed to our Medical Information department via Bristol-Myers Squibb Canada at 1-866-463-6267 or by fax at 1-888-267-6211.

Sincerely,

original signed by

Karen-Lesley Smith, MD, PhD, MBA
Vice-President, Scientific Affairs

Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime